Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells 12,980 Shares

Takeda Pharmaceutical Co. (NYSE:TAK) insider Nicola Deidre Petal Greenway sold 12,980 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $18.11, for a total transaction of $235,067.80. Following the completion of the transaction, the insider directly owned 40,049 shares in the company, valued at $725,287.39. The trade was a 24.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Nicola Deidre Petal Greenway also recently made the following trade(s):

• On Monday, August 10th, Nicola Deidre Petal Greenway sold 6,774 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $17.10, for a total value of $115,835.40.

Takeda Pharmaceutical Trading Up 1.7%

TAK traded up $0.32 during mid-day trading on Wednesday, hitting $18.36. 3,309,185 shares of the stock were exchanged, compared to its average volume of 3,178,624. The company has a market cap of $58.84 billion, a PE ratio of 54.01 and a beta of -0.08. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The firm’s fifty day moving average is $16.65 and its two-hundred day moving average is $17.16. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.17 by $0.30. The business had revenue of $7.50 billion during the quarter, compared to analyst estimates of $7.13 billion. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Equities analysts forecast that Takeda Pharmaceutical Co. will post 1.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on TAK shares. Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Finally, Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Institutional Investors Weigh In On Takeda Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Private Trust Co. NA lifted its holdings in shares of Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after purchasing an additional 783 shares during the last quarter. Parkside Financial Bank & Trust increased its position in Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after buying an additional 1,684 shares during the period. SHP Wealth Management purchased a new stake in Takeda Pharmaceutical in the fourth quarter valued at approximately $42,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after acquiring an additional 2,328 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after acquiring an additional 1,292 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.